Ignite Creation Date:
2024-05-06 @ 5:40 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05380024
Status:
UNKNOWN
Last Update Posted:
2022-08-18
First Post:
2022-05-13
Brief Title:
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Organization Data
Organization:
Peking University Cancer Hospital Institute
Class:
OTHER
Study ID:
BD-EN-IV0012
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking University Cancer Hospital Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Wu Nan
Responsible Party Title:
Clinical Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Peking University Cancer Hospital Institute
Old Name:
None
Old Organization:
None